Loading...
ARGX logo

argenx SEWBAG:ARGX Stock Report

Market Cap €44.2b
Share Price
€714.00
€846.98
15.7% undervalued intrinsic discount
1Y36.9%
7D6.8%
Portfolio Value
​
View

argenx SE

WBAG:ARGX Stock Report

Market Cap: €44.2b

argenx (ARGX) Stock Overview

A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. More details

ARGX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 66.2% below our estimate of its fair value

Earnings are forecast to grow 21.84% per year

Earnings grew by 55.1% over the past year

Risk Analysis

High level of non-cash earnings


ARGX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 73.0% undervalued intrinsic discount
5022.2%Revenue growth p.a.
1.7k
16
0
21
14d ago

argenx SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for argenx
Historical stock prices
Current Share Price€714.00
52 Week High€805.00
52 Week Low€457.20
Beta-0.087
1 Month Change15.35%
3 Month Change1.54%
1 Year Change36.94%
3 Year Change109.32%
5 Year Change195.04%
Change since IPO249.66%

Recent News & Updates

Recent updates

Shareholder Returns

ARGXAT BiotechsAT Market
7D6.8%3.2%2.5%
1Y36.9%39.1%37.0%

Return vs Industry: ARGX underperformed the Austrian Biotechs industry which returned 39.2% over the past year.

Return vs Market: ARGX matched the Austrian Market which returned 37.3% over the past year.

Price Volatility

Is ARGX's price volatile compared to industry and market?
ARGX volatility
ARGX Average Weekly Movement4.4%
Biotechs Industry Average Movement8.6%
Market Average Movement4.7%
10% most volatile stocks in AT Market7.4%
10% least volatile stocks in AT Market2.5%

Stable Share Price: ARGX has not had significant price volatility in the past 3 months compared to the Austrian market.

Volatility Over Time: ARGX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,863Tim Van Hauwermeirenargenx.com

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy.

argenx SE Fundamentals Summary

How do argenx's earnings and revenue compare to its market cap?
ARGX fundamental statistics
Market cap€44.19b
Earnings (TTM)€1.10b
Revenue (TTM)€3.60b
40.3x
P/E Ratio
12.3x
P/S Ratio

Is ARGX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARGX income statement (TTM)
RevenueUS$4.24b
Cost of RevenueUS$1.81b
Gross ProfitUS$2.42b
Other ExpensesUS$1.13b
EarningsUS$1.29b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

May 07, 2026

Earnings per share (EPS)20.78
Gross Margin57.16%
Net Profit Margin30.50%
Debt/Equity Ratio0%

How did ARGX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/16 03:54
End of Day Share Price 2026/04/16 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 53 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
null nullBaird